Atea Pharmaceuticals Inc(AVIR) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 9 at 5:45 PM ET (Korea 11/10 07:45)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -2.09 | Insider Own | 20.46% | Shs Outstand | 80.2M | Perf Week | 7.56% |
| Market Cap | 0.35B | Forward P/E | - | EPS next Y | 25.44% | Insider Trans | 0.04% | Shs Float | 63.8M | Perf Month | -14.37% |
| Enterprise Value | 0.13B | PEG | - | EPS next Q | -0.57 | Inst Own | 71.36% | Short Float | 4.81% | Perf Quarter | -12.67% |
| Income | -0.17B | P/S | - | EPS this Y | -2.32% | Inst Trans | -0.02% | Short Ratio | 10.91 | Perf Half Y | -18.48% |
| Sales | 0.00B | P/B | 1.73 | EPS next 5Y | 12.05% | ROA | -52.99% | Short Interest | 3.07M | Perf YTD | 23.53% |
| Book/sh | 2.55 | P/C | 1.61 | EPS past 3/5Y | -11.75% -71.02% | ROE | -58.14% | 52W High | -31.63% ($6.45) | Perf Year | 34.86% |
| Cash/sh | 2.74 | P/FCF | - | Sales past 3/5Y | - | ROIC | -80.96% | 52W Low | 53.66% ($2.87) | Perf 3Y | 47.49% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -29.71% | Gross Margin | - | Volatility(W/M) | 5.61% 5.86% | Perf 5Y | -59.62% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.24 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 8.13 | EPS Q/Q | 7.28% | Profit Margin | - | RSI (14) | 47.39 | Recom | 1.67 |
| Dividend Gr. 3/5Y | - | Current Ratio | 8.13 | Sales Q/Q | - | SMA20 | 2.35% ($4.31) | Beta | 0.7 | Target Price | $8.5 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/11/9 | SMA50 | -10.06% ($4.9) | Rel Volume | 0.87 | Prev Close | $4.31 |
| Employees | 55 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 20.79% - | SMA200 | -10.89% ($4.95) | Avg Volume(3M) | 0.28M | Price | $4.41 |
| IPO | 2020/10/30 | Option/Short | Yes/Yes | Trades | 2475 | Volume | 244,281 | Change | 2.32% |
🔬 Atea Pharmaceuticals (AVIR) is a U.S. clinical-stage biopharmaceutical company that focuses its entire organizational capabilities on discovering and advancing clinical development of orally administered antiviral therapeutics with differentiated mechanisms of action, targeting serious viral diseases with high unmet medical needs worldwide, including hepatitis C and hepatitis E.
Over the past 1 year, roughly in the middle
32% below its 1-year high.
Traded about as much as usual. That is 87% of its average volume.
AVIR has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by -2.3% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -59.6%. The S&P 500 did +61% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 71.4%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #248 of 597 in the industry
Based on market cap of $354M.
AVIR#248 Atea Pharmaceuticals Inc $354M PER - 
AUTL#249 Autolus Therapeutics plc ADR $351M PER - 
IRD#250 Opus Genetics Inc $349M PER - 
GALT#251 Galectin Therapeutics Inc $349M PER - 
PROK#252 ProKidney Corp $348M PER - 
FAQ
What kind of company is AVIR?
AVIR belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of AVIR?
The market cap of AVIR is approximately $354M, ranking 3,461 within its sector.
What is the 52-week high and low for AVIR?
AVIR has recorded a 52-week high of $6.45 and a low of $2.87.
